Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biosyent Inc's subsidiary receives Health Canada approval to market New Urgent Care Product


Thursday, 12 Jun 2014 08:00am EDT 

Biosyent Inc:Says its subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics Products Directorate approval to market new urgent care product.This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval.Newly approved urgent care drug is supplied in a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings.These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies and will be marketed by BioSyent Pharma's Hospital Division.It is anticipated that this new product will be launched in late 2014 or early 2015. 

Company Quote

12.33
0.38 +3.18%
18 Sep 2014